Ford Posts Strong Earnings But Suspends Guidance Due To Tariffs
Ford Motor Co. (F) reported strong financial results for this year’s first quarter but suspended its forward guidance due to continued uncertainty related to tariffs and trade turmoil. The Detroit automaker announced earnings per share (EPS) of $0.14 U.S., which blew past the consensus forecast among analysts that called for a profit of $0.02 U.S. a share. Revenue in the January through March period totaled $37.42 billion U.S., which surpassed the $36.21 billion U.S. expected on Wall Street.Despite the strong print, Ford’s management team suspended the company’s 2025 financial guidance, saying they expect a $2.5 billion U.S. impact this year from U.S. President Donald Trump’s tariffs on foreign made vehicles and automotive parts.Ford executives also said that they plan to offset $1 billion U.S. in added costs from tariffs through pricing actions that could see the average cost of a vehicle sold in the U.S. rise. The company added that it is grappling with “near-term risks” that include potential supply chain disruptions and possible impacts from retaliatory tariffs imposed by countries outside America. Ford’s estimated tariff impact of $2.5 billion U.S. is less than the $4 billion U.S. to $5 billion U.S. forecast by rival General Motors (GM). Ford imports fewer vehicles than GM. Also in the first quarter, Ford’s electric vehicle unit narrowed its loss from $1.33 billion U.S. a year ago to $849 million U.S. during this year’s first quarter. The stock of Ford Motor Co. has risen 5% year-to-date and currently trades at $10.17 U.S. a share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


